Literature DB >> 22249131

Long-term prognosis of autoimmune pancreatitis in terms of glucose tolerance.

Kenji Hirano1, Akihiro Isogawa, Minoru Tada, Hiroyuki Isayama, Naminatsu Takahara, Koji Miyabayashi, Suguru Mizuno, Dai Mohri, Kazumichi Kawakubo, Takashi Sasaki, Hirofumi Kogure, Natsuyo Yamamoto, Naoki Sasahira, Nobuo Toda, Rie Nagano, Hiroshi Yagioka, Yoko Yashima, Tsuyoshi Hamada, Yukiko Ito, Kazuhiko Koike.   

Abstract

OBJECTIVE: Glucose intolerance is often observed in autoimmune pancreatitis (AIP), although its long-term prognosis after steroid treatment (ST) is still unclear.
METHODS: A total of 47 patients with AIP were enrolled. On the basis of the change in hemoglobin A1c (HbA1c) and the use of diabetic medication, prognosis was classified into 3 categories, namely, "improved," "aggravated," and "unchanged." The relation between the result of an initial glucagon tolerance test (ΔCPR) and the later use of insulin during maintenance ST was examined in 20 patients. The transitions of homeostasis model assessment β cell and insulin resistance (HOMA-β and HOMA-R) were analyzed in 16 patients.
RESULTS: Glucose tolerance was improved in 6 patients (13%), aggravated in 9 patients (19%), and unchanged in 32 patients (68%). All patients with ΔCPR less than 0.6 ng/mL were obliged to use insulin even after long-term observation, whereas all patients with ΔCPR more than 1.0 ng/mL were free from insulin therapy. Moreover, HOMA-β showed significant improvement after ST (43.9% → 56.0% in median, P = 0.030), and HOMA-R showed significant aggravation (1.30 → 1.78, P = 0.039).
CONCLUSIONS: Glucose tolerance that is too severely damaged may not recover fully even after ST. Thus, ST should be performed to preserve insulin secretion at the early stage of AIP.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22249131     DOI: 10.1097/MPA.0b013e31823bcdee

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  15 in total

1.  Insulin secretion improvement during steroid therapy for autoimmune pancreatitis according to the onset of diabetes mellitus.

Authors:  Kensaku Noguchi; Yousuke Nakai; Suguru Mizuno; Hiroyuki Isayama; Kenji Hirano; Sachiko Kanai; Tomoka Nakamura; Rie Uchino; Naminatsu Takahara; Hirofumi Kogure; Minoru Tada; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2019-08-30       Impact factor: 7.527

2.  Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts.

Authors:  Hyon K Choi; John H Stone; Zachary S Wallace; Yuqing Zhang; Cory A Perugino; Ray Naden
Journal:  Ann Rheum Dis       Date:  2019-01-05       Impact factor: 19.103

3.  Long-term surgical outcomes of patients with type 1 autoimmune pancreatitis.

Authors:  Fumihiko Miura; Keiji Sano; Hodaka Amano; Naoyuki Toyota; Keita Wada; Susumu Kadowaki; Makoto Shibuya; Tadahiro Takada; Yurie Soejima; Fukuo Kondo
Journal:  World J Surg       Date:  2013-01       Impact factor: 3.352

4.  Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis.

Authors:  Phil A Hart; Terumi Kamisawa; William R Brugge; Jae Bock Chung; Emma L Culver; László Czakó; Luca Frulloni; Vay Liang W Go; Thomas M Gress; Myung-Hwan Kim; Shigeyuki Kawa; Kyu Taek Lee; Markus M Lerch; Wei-Chih Liao; Matthias Löhr; Kazuichi Okazaki; Ji Kon Ryu; Nicolas Schleinitz; Kyoko Shimizu; Tooru Shimosegawa; Roy Soetikno; George Webster; Dhiraj Yadav; Yoh Zen; Suresh T Chari
Journal:  Gut       Date:  2012-12-11       Impact factor: 23.059

5.  A case of IgG4-related hepatic inflammatory pseudotumor replaced by an abscess after steroid treatment.

Authors:  Masayuki Shibata; Hiroyuki Matsubayashi; Tsuyoshi Aramaki; Katsuhiko Uesaka; Naoyuki Tsutsumi; Keiko Sasaki; Hiroyuki Ono
Journal:  BMC Gastroenterol       Date:  2016-08-02       Impact factor: 3.067

6.  Prognosis of type 1 autoimmune pancreatitis after corticosteroid therapy-induced remission in terms of relapse and diabetes mellitus.

Authors:  Masaki Miyazawa; Hajime Takatori; Tetsuro Shimakami; Kazunori Kawaguchi; Kazuya Kitamura; Kuniaki Arai; Koichiro Matsuda; Taku Sanada; Takeshi Urabe; Katsuhisa Inamura; Takashi Kagaya; Hideki Mizuno; Uichiro Fuchizaki; Taro Yamashita; Yoshio Sakai; Tatsuya Yamashita; Eishiro Mizukoshi; Masao Honda; Shuichi Kaneko
Journal:  PLoS One       Date:  2017-11-22       Impact factor: 3.240

7.  Autoimmune pancreatitis can develop into chronic pancreatitis.

Authors:  Masahiro Maruyama; Takayuki Watanabe; Keita Kanai; Takaya Oguchi; Jumpei Asano; Tetsuya Ito; Yayoi Ozaki; Takashi Muraki; Hideaki Hamano; Norikazu Arakura; Shigeyuki Kawa
Journal:  Orphanet J Rare Dis       Date:  2014-05-21       Impact factor: 4.123

8.  Total cholesterol level for assessing pancreatic insufficiency due to chronic pancreatitis.

Authors:  Kenji Hirano; Tomotaka Saito; Suguru Mizuno; Minoru Tada; Naoki Sasahira; Hiroyuki Isayama; Miho Matsukawa; Gyotane Umefune; Dai Akiyama; Kei Saito; Shuhei Kawahata; Naminatsu Takahara; Rie Uchino; Tsuyoshi Hamada; Koji Miyabayashi; Dai Mohri; Takashi Sasaki; Hirofumi Kogure; Natsuyo Yamamoto; Yosuke Nakai; Kazuhiko Koike
Journal:  Gut Liver       Date:  2014-04-23       Impact factor: 4.519

Review 9.  Long-term outcomes of autoimmune pancreatitis.

Authors:  Tsukasa Ikeura; Hideaki Miyoshi; Masaaki Shimatani; Kazushige Uchida; Makoto Takaoka; Kazuichi Okazaki
Journal:  World J Gastroenterol       Date:  2016-09-14       Impact factor: 5.742

10.  Transpapillary biliary stenting is a risk factor for pancreatic stones in patients with autoimmune pancreatitis.

Authors:  Hiroyuki Matsubayashi; Yoshihiro Kishida; Tomohiro Iwai; Katsuyuki Murai; Masao Yoshida; Kenichiro Imai; Yusuke Yamamoto; Masataka Kikuyama; Hiroyuki Ono
Journal:  Endosc Int Open       Date:  2016-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.